GLP-1及其类型:性是否重要?
Stina Börchers1, Karolina P Skibicka1,2,3
1Department of Physiology/Metabolic Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 41390 Gothenburg, Sweden.
Endocrinology
|December 23, 2024
概括
类似于葡萄糖类1 (GLP-1) 的类似物在治疗肥胖和糖尿病方面表现有前途. 虽然存在很少的品质性差异,但注意到了定量差异和雌激素相互作用,需要对女性进行更多研究.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖和糖尿病呈现出性别特异性的差异.
- 类似于葡萄糖类1 (GLP-1) 的类似物是这些疾病的有前途的治疗类.
- 了解GLP-1作用中的性别差异至关重要.
研究的目的:
- 审查GLP-1及其类型的内源性和治疗作用中的性别差异.
- 要突出关于这些差异的临床前和临床证据.
- 检查GLP-1类型在情绪和生殖功能中的作用,考虑到性别差异.
主要方法:
- 对GLP-1中性别差异的人类研究和动物研究的综述.
- 对GLP-1系统中性别差异机制的临床前数据的分析.
- 关于GLP-1对肥胖,糖尿病和心血管疾病的类似效应的临床证据的讨论.
主要成果:
- 在已批准的GLP-1类别的治疗效果中发现了有限的定性性别差异.
- 对于GLP-1类似物和与雌激素的相互作用的反应中,正在出现量的性别差异.
- 在女性模型和女性GLP-1科学方面存在显著的数据缺口.
结论:
- 虽然GLP-1类似物显示出有效性,但定量性差异和雌激素相互作用需要进一步研究.
- 迫切需要更多的研究,特别是在女性人群中,以解决现有的数据缺口.
- 未来的研究应该集中在针对GLP-1基疗法的性别特异性反应上.
相关概念视频
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K


